Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072888854> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2072888854 endingPage "1419" @default.
- W2072888854 startingPage "1418" @default.
- W2072888854 abstract "Natalizumab (Tysabri®, Biogen-Dompe, Cambridge, MA) is the first selective adhesion-molecule inhibitor approved for the treatment of multiple sclerosis (MS). Although undoubtedly efficacious in clinical and radiologic control of MS, its use raised some concerns regarding the potential occurrence of opportunistic infection in the exposed population, referring in particular to progressive multifocal leukoencephalopathy (PML).1Toxoplasma gondii (TG) is a protozoan parasite that infects up to a third of the world's immunocompetent population with usually mild or no symptoms. On the contrary, its reactivation is a threatening condition that affects immunocompromised subjects, namely persons with HIV, organ transplant recipients, people with neoplastic disease, or people on a prolonged steroid treatment.2,3Here we discuss the reactivation of ocular toxoplasmosis (OT) during natalizumab treatment.### Case report.The patient is a 28-year-old man with relapsing-remitting MS. His previous medical history includes alcohol abuse and no malignancies, signs of immunodeficiency, or temporary stays abroad.He first visited our center in 2004 due to a right subacute sensory-motor syndrome. We performed brain MRI and CSF analysis along with screening for autoimmune, infectious, dysmetabolic, and thrombophilic diseases. All of them proved to be compatible with the diagnosis of clinically isolated syndrome suggestive for MS. After a high-dose steroid course followed by symptoms remission, he was treated with interferon beta 1b …" @default.
- W2072888854 created "2016-06-24" @default.
- W2072888854 creator A5003503698 @default.
- W2072888854 creator A5034865507 @default.
- W2072888854 creator A5043940401 @default.
- W2072888854 creator A5075331552 @default.
- W2072888854 date "2009-09-23" @default.
- W2072888854 modified "2023-10-18" @default.
- W2072888854 title "OCULAR TOXOPLASMOSIS DURING NATALIZUMAB TREATMENT" @default.
- W2072888854 cites W1971878303 @default.
- W2072888854 cites W1996787636 @default.
- W2072888854 cites W2073645035 @default.
- W2072888854 cites W2169082675 @default.
- W2072888854 doi "https://doi.org/10.1212/wnl.0b013e3181bd114f" @default.
- W2072888854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19776379" @default.
- W2072888854 hasPublicationYear "2009" @default.
- W2072888854 type Work @default.
- W2072888854 sameAs 2072888854 @default.
- W2072888854 citedByCount "31" @default.
- W2072888854 countsByYear W20728888542012 @default.
- W2072888854 countsByYear W20728888542013 @default.
- W2072888854 countsByYear W20728888542014 @default.
- W2072888854 countsByYear W20728888542015 @default.
- W2072888854 countsByYear W20728888542016 @default.
- W2072888854 countsByYear W20728888542017 @default.
- W2072888854 countsByYear W20728888542019 @default.
- W2072888854 countsByYear W20728888542021 @default.
- W2072888854 countsByYear W20728888542022 @default.
- W2072888854 countsByYear W20728888542023 @default.
- W2072888854 crossrefType "journal-article" @default.
- W2072888854 hasAuthorship W2072888854A5003503698 @default.
- W2072888854 hasAuthorship W2072888854A5034865507 @default.
- W2072888854 hasAuthorship W2072888854A5043940401 @default.
- W2072888854 hasAuthorship W2072888854A5075331552 @default.
- W2072888854 hasConcept C159047783 @default.
- W2072888854 hasConcept C16005928 @default.
- W2072888854 hasConcept C203014093 @default.
- W2072888854 hasConcept C2778062946 @default.
- W2072888854 hasConcept C2780640218 @default.
- W2072888854 hasConcept C2781004633 @default.
- W2072888854 hasConcept C71924100 @default.
- W2072888854 hasConceptScore W2072888854C159047783 @default.
- W2072888854 hasConceptScore W2072888854C16005928 @default.
- W2072888854 hasConceptScore W2072888854C203014093 @default.
- W2072888854 hasConceptScore W2072888854C2778062946 @default.
- W2072888854 hasConceptScore W2072888854C2780640218 @default.
- W2072888854 hasConceptScore W2072888854C2781004633 @default.
- W2072888854 hasConceptScore W2072888854C71924100 @default.
- W2072888854 hasIssue "17" @default.
- W2072888854 hasLocation W20728888541 @default.
- W2072888854 hasLocation W20728888542 @default.
- W2072888854 hasOpenAccess W2072888854 @default.
- W2072888854 hasPrimaryLocation W20728888541 @default.
- W2072888854 hasRelatedWork W1985660084 @default.
- W2072888854 hasRelatedWork W1989037087 @default.
- W2072888854 hasRelatedWork W2037777985 @default.
- W2072888854 hasRelatedWork W2151867003 @default.
- W2072888854 hasRelatedWork W2164906127 @default.
- W2072888854 hasRelatedWork W2948529275 @default.
- W2072888854 hasRelatedWork W3016997033 @default.
- W2072888854 hasRelatedWork W4255590419 @default.
- W2072888854 hasRelatedWork W4307344424 @default.
- W2072888854 hasRelatedWork W4311483557 @default.
- W2072888854 hasVolume "73" @default.
- W2072888854 isParatext "false" @default.
- W2072888854 isRetracted "false" @default.
- W2072888854 magId "2072888854" @default.
- W2072888854 workType "article" @default.